Group 1 - The core point of the article is that BlackRock has increased its long position in Luoyang Luanchuan Molybdenum Co., Ltd. - H shares from 8.63% to 9.03% as of March 20, 2026 [1]

Core Insights - The company reported total revenue of 629 million yuan for 2025, marking a 20% year-on-year increase and achieving growth for four consecutive years [1][6] - The Robotaxi business is entering a phase of explosive growth, with annual revenue reaching 116 million yuan in 2025, a 129% increase, and passenger fare revenue increasing nearly 400% [1][6] - The company aims to expand its Robotaxi fleet to over 3,000 vehicles and deploy in more than 20 cities globally by the end of 2026 [1][6] Revenue and Growth - Total revenue for 2025 was 629 million yuan, with a 20% increase year-on-year [1][6] - Robotaxi revenue for 2025 was 116 million yuan, up 129% from the previous year, with Q4 revenue of 46.6 million yuan accounting for 40% of the annual total [1][6] - The company achieved its first quarterly profit in Q4 2025, with a net profit of 528 million yuan [10] Robotaxi Business Expansion - The seventh-generation Robotaxi began commercial operations in November 2025, achieving single-vehicle profitability in Guangzhou [2][7] - By early 2026, the Robotaxi operations in Shenzhen saw record-breaking performance, with paid order volume surpassing the total for 2025 [2][7] - The company has initiated a dual-engine strategy to ensure growth momentum in the Robotaxi business, focusing on expanding into over 20 cities by the end of 2026 [2][8] Fleet and Technology Development - The company is utilizing a co-built fleet model to rapidly expand its Robotaxi fleet, partnering with companies like Toyota and Verne [3][8] - As of now, the Robotaxi fleet has exceeded 1,400 vehicles, with plans to add 1,000 units of the seventh-generation Toyota model by the end of the year [3][8] - The company’s self-developed technology enhances user experience and operational efficiency, contributing to the growth of the Robotaxi business [9] Robotruck and Other Revenue Streams - The Robotruck business generated 284 million yuan in revenue for 2025, with ongoing expansion into various commercial applications [4][9] - Revenue from technology licensing and application services reached 229 million yuan, a 19.7% increase year-on-year, driven by a fivefold increase in the delivery of autonomous driving domain controllers [5][10] - The company maintains a strong financial position with cash and investments totaling 10.593 billion yuan as of December 31, 2025, supporting its growth initiatives [10]

Core Viewpoint - The global marine economy is rapidly transforming from traditional marine industries to marine technology, high-end manufacturing, and modern shipping services, with ports and shipping as key hubs for connectivity and logistics [1][3]. Group 1: Industry Transformation - The shipping industry is recognized as a crucial platform for cooperation and logistics, facilitating the integration of marine emerging industries and traditional shipping [1][3]. - China COSCO Shipping Group emphasizes the importance of dual empowerment between the shipping industry and emerging marine industries for integrated development [1][3]. Group 2: Global Operations and Infrastructure - China COSCO Shipping operates 58 global investment terminals, with 22 located in countries and regions along the Belt and Road Initiative, creating a broad and efficient global network [1][3]. - The company aims to enhance the hub capabilities of its ports and optimize the integration of land-sea connections, port-port connections, and port-industry connections for high-quality development of the blue economy [1][3]. Group 3: Green Development Initiatives - China COSCO Shipping prioritizes green development, promoting low-carbon transformation across the entire logistics chain, including ports and vessels [2][4]. - The company has invested in the first green smart terminal in South America, featuring 100% electrification of major port machinery and full digital operation to achieve low-carbon and pollution-free operations [2][4]. - By 2025, the company plans for clean energy to account for over 33% of new power operations, and it has successfully launched the world's first methanol dual-fuel container ship [2][4].

里昂发布研报称，中国金茂（00817）连续两年录得盈利，合约销售亦重回增长轨道。整体而言，该行 相信公司正处于清晰的复苏路径，而增持计划亦将管理层与股东的利益绑定，有望推动估值进一步重 估，加上公司的央企背景，可进一步增强投资者信心。目标价由1.32港元上调至1.52港元，重申"跑赢大 市"评级。该行预期，随着高成本库存大致消化，发展物业利润率将触底反弹，预计优质土地储备将支 持利润率保持韧性，带动未来数年盈利增长。 责任编辑：史丽君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 里昂发布研报称，中国金茂（00817）连续两年录得盈利，合约销售亦重回增长轨道。整体而言，该行 相信公司正处于清晰的复苏路径，而增持计划亦将管理层与股东的利益绑定，有望推动估值进一步重 估，加上公司的央企背景，可进一步增强投资者信心。目标价由1.32港元上调至1.52港元，重申"跑赢大 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 市"评级。该行预期，随着高成本库存大致消化，发展物业利润率将触底反弹，预计优质土地储备将支 持利润率保持韧性，带动未来数年盈利增长。 责任编辑：史丽君 ...

Core Viewpoint - Israel has removed Iranian Foreign Minister Amir-Abdollahian and Iranian Parliament Speaker Ghalibaf from its assassination list following a request from Pakistan to the U.S. [1] Group 1 - Israeli authorities had previously intended to carry out a targeted operation against the two Iranian officials, as they had obtained their location information [1] - Pakistan communicated to the U.S. that if these two individuals were eliminated, there would be no dialogue partners left, prompting the U.S. to request Israel to refrain from such actions [1] - The U.S. officials indicated that the deadline for removing the two from the assassination list was "4 to 5 days" [1] Group 2 - Pakistan's Prime Minister Shahbaz expressed readiness to facilitate talks aimed at resolving the current conflict, contingent upon the agreement of both the U.S. and Iran [1]

Group 1 - Major companies such as Rohm, Toshiba, and Mitsubishi Electric are expected to announce the initiation of related negotiations as early as Friday [1]

Core Viewpoint - The report from Jefferies indicates that Nongfu Spring (09633) has shown significant financial growth in 2025, with revenue increasing by 22.5% to 52.6 billion RMB and net profit rising by 32.7% to 15.9 billion RMB, suggesting strong performance in the second half of 2025 [1][4] Financial Performance - Revenue for 2025 reached 52.6 billion RMB, marking a 22.5% increase year-on-year [1][4] - Net profit for the same year was 15.9 billion RMB, reflecting a year-on-year growth of 32.7% [1][4] - Projections for the second half of 2025 indicate revenue and net profit growth of 30% and 42% respectively [1][4] Future Outlook - Management forecasts double-digit sales growth for 2026, with bottled water sales expected to return to or exceed 2023 levels [1][4] - Due to fluctuations in commodity prices, particularly PET, the company has not provided guidance on profit margins for 2026 [1][4] - As 2026 marks the 30th anniversary of the company, Nongfu Spring plans to implement more promotional strategies to enhance consumer engagement [1][4] Rating and Target Price - Jefferies maintains a "Hold" rating for Nongfu Spring, with a slight increase in the target price from 50 HKD to 50.5 HKD [1][4]

Group 1 - The core viewpoint of the report is that Kuaishou-W (01024) exceeded expectations in its Q4 2025 financial results, with total revenue and adjusted EBIT growing by 12% and 20% year-on-year, reaching 39.6 billion and 6 billion RMB respectively, which is 2% higher than the firm's estimates [1][3] - The annualized revenue for Kuaishou as of December has reached 240 million USD, and it is expected to more than double in 2026, indicating that Kuaishou will become a new growth engine [1][3] - The firm maintains an "outperform" rating on Kuaishou, reflecting confidence in its future performance [1][3]

Core Viewpoint - The company, Anhui Jialiqi Advanced Composite Materials Technology Co., Ltd., is positioned in the aerospace composite parts market, focusing on military applications and has established a strong foundation for future growth through early market entry and technological capabilities [2][11]. Company Overview - Anhui Jialiqi was founded on March 30, 2004, and is located in Suzhou, Anhui Province. The company specializes in the research, production, and sales of advanced composite materials, with its main products being aircraft and missile composite parts [8][16]. - The company's revenue composition includes 95.89% from aircraft composite parts, 4.05% from manufacturing and technical services, and 0.05% from missile composite parts [16]. Business Development - The company has been involved in military product development since 2012, focusing on various models of aerospace composite parts used in fighter jets, transport aircraft, drones, and missiles [2][11]. - Jialiqi has successfully expanded its customer base in the automotive sector and signed a technology development contract with Guangdong Huitian Aerospace Technology Co., Ltd., indicating potential new growth areas [12]. Industry Position - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for small and medium-sized enterprises that excel in niche markets and possess strong innovation capabilities [3][12]. - The aerospace composite parts market is expected to grow as collaboration with major aircraft manufacturers increases, providing Jialiqi with a competitive advantage [2][11]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 565 million yuan, representing a year-on-year increase of 29.47%. However, the net profit attributable to shareholders decreased by 45.97% to approximately 42.47 million yuan [16]. - As of September 30, 2025, the company had a total of 10,000 shareholders, with a decrease of 6.56% from the previous period, while the average number of circulating shares per person increased by 175.41% [16][17].

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for its Dihydroxypropyl Theophylline Injection, which is approved for production [1] Group 1: Product Approval - The drug is classified as a Class 3 chemical drug and is indicated for the relief of symptoms in bronchial asthma and asthmatic bronchitis [1] - As of the announcement date, the company has invested approximately 3.14 million yuan in research and development for this product [1] Group 2: Market Potential - According to IQVIA data, the projected hospital procurement amount for this drug type in mainland China is 325 million yuan by 2025 [1] - The company believes that the approval of this product will enhance its market competitiveness and provide experience for future generic drug applications [1] Group 3: Risks - The company acknowledges that there are risks related to sales not meeting expectations due to policy and market factors [1]